-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Abbott Laboratories Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue |
|
$34.61B | $43.08B | $43.65B | $40.11B |
| Cost of Revenue |
|
$15.00B | $18.54B | $19.14B | $17.98B |
| Gross Profit |
|
$19.61B | $24.54B | $24.51B | $22.13B |
| Research & Development |
|
$2.42B | $2.74B | $2.89B | $2.74B |
| Selling,General & Administrative |
|
$9.70B | $11.32B | $11.25B | $10.95B |
| Operating Expense |
|
$14.25B | $16.11B | $16.15B | $15.66B |
| Operating Income |
|
$5.36B | $8.43B | $8.36B | $6.48B |
| Net Income |
|
$4.50B | $7.07B | $6.93B | $5.72B |
Abbott Laboratories Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$7.15B | $10.25B | $10.17B | $7.28B |
| Inventories |
|
$5.01B | $5.16B | $6.17B | $6.57B |
| Total Current Assets |
|
$20.44B | $24.24B | $25.22B | $22.67B |
| Property,Plant and Equipment |
|
$9.03B | $8.96B | $9.16B | $11.28B |
| Goodwill |
|
$23.74B | $23.23B | $22.80B | $23.68B |
| Total Assets |
|
$72.55B | $75.20B | $74.44B | $73.21B |
| Total Liabilities |
|
$39.55B | $39.17B | $37.53B | $34.39B |
| Retained Earnings |
|
$27.63B | $31.53B | $35.26B | $37.55B |
| Total Shareholder Equity |
|
$32.78B | $35.80B | $36.69B | $38.60B |
| Common Stock |
|
$24.15B | $24.47B | $24.71B | $24.87B |
Abbott Laboratories Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$3.33B | $3.54B | $3.27B | $3.24B |
| Dividends Payout |
|
-$2.56B | -$3.20B | -$3.31B | -$3.56B |
| Capital Expenditures (Capex) |
|
-$2.18B | -$1.89B | -$1.78B | -$2.20B |
| Free Cash Flow (FCF) |
|
$5.72B | $8.65B | $7.80B | $5.06B |
Abbott Laboratories Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gross Profit |
|
$19.61B | $24.54B | $24.51B | $22.13B |
| Gross Profit Margin (%) |
|
56.65% | 56.97% | 56.15% | 55.18% |
| Operating Income |
|
$5.36B | $8.43B | $8.36B | $6.48B |
| Operating Income Margin (%) |
|
15.48% | 19.56% | 19.16% | 16.15% |
| Net Income |
|
$4.50B | $7.07B | $6.93B | $5.72B |
| Net Income Margin (%) |
|
12.99% | 16.42% | 15.88% | 14.27% |
| EBITDA |
|
$8.79B | $12.74B | $12.38B | $10.61B |
| EBITDA Margin (%) |
|
21.94% | 24.95% | 24.50% | 26.44% |
Abbott Laboratories Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
13.71% | 19.75% | 18.90% | 14.83% |
| Return on Assets (ROA) |
|
6.20% | 9.40% | 9.31% | 7.82% |
| Debt to Equity |
|
57.18% | 50.42% | 45.72% | 38.03% |
| Debt to total asset |
|
25.84% | 24.00% | 22.53% | 20.05% |
| Enterprise value to revenue |
|
5.98 | 6.01 | 4.59 | 4.98 |
| Enterprise value to EBITDA |
|
23.55 | 20.33 | 16.18 | 18.84 |
| Enterprise value |
|
$206.94B | $259.02B | $200.30B | $199.85B |
| Cash to Debt |
|
42.15% | 58.35% | 57.12% | 49.47% |
| Tax Rate (%) |
|
10.00% | 13.88% | 16.53% | 14.12% |
| Payout Ratio |
|
56.95% | 45.28% | 47.73% | 62.14% |
